These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 7548749)
81. Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity. Gravemann U; Volland J; Nau H Neurotoxicol Teratol; 2008; 30(5):390-4. PubMed ID: 18455366 [TBL] [Abstract][Full Text] [Related]
82. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Bjorge SM; Baillie TA Biochem Biophys Res Commun; 1985 Oct; 132(1):245-52. PubMed ID: 3933498 [TBL] [Abstract][Full Text] [Related]
83. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity. Fisher E; Siemes H; Pund R; Wittfoht W; Nau H Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752 [TBL] [Abstract][Full Text] [Related]
84. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Ponchaut S; van Hoof F; Veitch K Biochem Pharmacol; 1992 Jun; 43(11):2435-42. PubMed ID: 1610408 [TBL] [Abstract][Full Text] [Related]
85. Vitamin U, a novel free radical scavenger, prevents lens injury in rats administered with valproic acid. Tunali S; Kahraman S; Yanardag R Hum Exp Toxicol; 2015 Sep; 34(9):904-10. PubMed ID: 25504687 [TBL] [Abstract][Full Text] [Related]
86. Formulations of valproate alter valproate metabolism: a single oral dose kinetic study. Nagai G; Ono S; Yasui-Furukori N; Nakamura A; Mihara K; Kondo T Ther Drug Monit; 2009 Oct; 31(5):592-6. PubMed ID: 19704403 [TBL] [Abstract][Full Text] [Related]
87. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944 [TBL] [Abstract][Full Text] [Related]
88. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Granneman GR; Wang SI; Kesterson JW; Machinist JM Hepatology; 1984; 4(6):1153-8. PubMed ID: 6437961 [TBL] [Abstract][Full Text] [Related]
89. Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine. Lee MS; Jung BH; Chung BC; Cho SH; Kim KY; Kwon OS; Nugraha B; Lee YJ Int J Toxicol; 2009; 28(5):392-404. PubMed ID: 19605889 [TBL] [Abstract][Full Text] [Related]
90. Carnitine in the treatment of valproic acid-induced toxicity. Lheureux PE; Hantson P Clin Toxicol (Phila); 2009 Feb; 47(2):101-11. PubMed ID: 19280426 [TBL] [Abstract][Full Text] [Related]
91. Studies on the extra-mitochondrial CoA -ester formation of valproic and Delta4 -valproic acids. Aires CC; Ruiter JP; Luís PB; ten Brink HJ; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF Biochim Biophys Acta; 2007 Apr; 1771(4):533-43. PubMed ID: 17321204 [TBL] [Abstract][Full Text] [Related]
92. Valproate-induced liver injury: modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen. Abdel-Dayem MA; Elmarakby AA; Abdel-Aziz AA; Pye C; Said SA; El-Mowafy AM Drugs R D; 2014 Jun; 14(2):85-94. PubMed ID: 24733439 [TBL] [Abstract][Full Text] [Related]
93. Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression. Jolly RA; Ciurlionis R; Morfitt D; Helgren M; Patterson R; Ulrich RG; Waring JF Toxicol Pathol; 2004; 32 Suppl 2():19-25. PubMed ID: 15503661 [TBL] [Abstract][Full Text] [Related]
94. Early structural and functional changes in liver of rats treated with a single dose of valproic acid. Jezequel AM; Bonazzi P; Novelli G; Venturini C; Orlandi F Hepatology; 1984; 4(6):1159-66. PubMed ID: 6437962 [TBL] [Abstract][Full Text] [Related]
95. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Amini-Shirazi N; Ghahremani MH; Ahmadkhaniha R; Mandegary A; Dadgar A; Abdollahi M; Shadnia S; Pakdaman H; Kebriaeezadeh A Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621 [TBL] [Abstract][Full Text] [Related]
96. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Aires CC; Ijlst L; Stet F; Prip-Buus C; de Almeida IT; Duran M; Wanders RJ; Silva MF Biochem Pharmacol; 2010 Mar; 79(5):792-9. PubMed ID: 19854160 [TBL] [Abstract][Full Text] [Related]
97. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse. Nau H Teratology; 1986 Feb; 33(1):21-7. PubMed ID: 3090732 [TBL] [Abstract][Full Text] [Related]
98. Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. Silva MF; Ijlst L; Allers P; Jakobs C; Duran M; de Almeida IT; Wanders RJ Drug Metab Dispos; 2004 Nov; 32(11):1304-10. PubMed ID: 15483197 [TBL] [Abstract][Full Text] [Related]
99. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. Knapp AC; Todesco L; Beier K; Terracciano L; Sägesser H; Reichen J; Krähenbühl S J Pharmacol Exp Ther; 2008 Feb; 324(2):568-75. PubMed ID: 17986647 [TBL] [Abstract][Full Text] [Related]
100. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia? Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]